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Review: 
METABOLISM AND PllARMACOKINETICS OF PAEONIFLORIN, 
A BIOACTIVE COMPONENT FROM PEONY ROOTS 
MESELHY R. MESELHY* AND MASAO HAτTORI 
ABSTRACT 
Paeoniflorin (PF, yield up to 5.8% of出e批yweight) is the major and the most important component of peony 
rots. Recent studies demonstrate血atPF improves the spatial and memory deficits in rodents and suggest possible 
utilization of this agent in the treatment of certain types of dementia. The understanding of the metabolism and 
pharmacokinetics of出isagent may provide insights into the mechanism of its efects. Due to the poor absorption from 
intestine, PF is subjected to the metabolism to give three metabolites, by intestinal bacteria. Paeonimetabolin I (PM-I), 
血em司orintestinal bacterial metabolite of PF showed anticonvulsant action. And in the presence of thiol compounds, 
intestinal bacteria were found capable of transforming PF to more potent anticonvulsant thiopaeonimetabolin-1 deriva-
tives. The ph紅macokineticsof PF and PM-I were investigated in rats by enzyme immunoassay (EIA), and were dose-
dependent. PM・Iwas not detected in the rat plasma after intravenous (i. v.) administration of PF, and a significant 
difference in the plasma concentration of PM-I was observed between germ-free and conventional rats. After oral and 
i. v. administration of PM-I to rats, it was found at high concentrations in the plasma. 
INTRODUCTION 
Paeoniae Radix, the dried roots of Paeonia 
lactiflora PALLAS (Paeoniaceae ),is a potential 
crude drug traditionally used as a component of 
Japanese and Chinese prescriptions to treat abdomi-
nal pain and certain types of dementia.1-4 Paeoniflo-
rin (PF, 1) is the m勾orcomponent in this Radix. 
The yield of PF (1) was found to be variable, and 
depends not only on plant species, but also on the 
stage of growth, the season of collection and the 
method used for processing. Phylogenetically, plant 
species with higher PF contents were mainly in the 
genus Paeonia, P. lactiflora and P. veitchi being 
the two with the highest contents. 5 The maximum 
yield of PF (1) from cultivated P. lactiflora amounts 
to 5.8% of plant dry weight.5-7 Plants cultivated for 
one year and collected in spring or fal contain the 
highest percentage of PF (1) relative to that culti-
vated for three ye紅s.Wine-processed roots contain 
higher percentage of PF (1) than those in raw or 
roasted roots. 8 When determined by HPLC, the 
m司orcomponents of P. lactiflora (higher content is 
in the core wood) were found to be PF (1), 
albiflorin (2) and pentagalloylglucose, while those 
of P. vitchii (higher content is in the cortex) were 
PF (1), pentagalloylglucose and oxypaeoniflorin (3) 
(Ch訂t1).9 The content of PF (1) in herbal prescrip-
tions (Kampo medicine in Japanese) containing 
peony roots was also determined by HPLC. After 
almost three decades of its discovery, PF (1) was 
synthesized by Corey and Wu, 10 and then by 
Hatakeyama et al. 1 
Animal experiments indicated diverse activi-
ties of peony roots and PF (1) as well. The crude 
ex仕actof peony roots was repo目edto have improv-
ing effects on memoηdeficits.3・4 Besides, anti-
inflammatory12 and immuno・modulating effects 
were also reported. 13 The water-soluble fraction of 
the methanol extract of peony roots significantly 
improved spatial cognition caused by M 1-receptor 
antagonist scopolamine in rats. 14 Ohta et al. found 
that such a beneficial effect was attributed mainly 
to the aqueous ex仕actof peony roots and the water-
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soluble glycosides such as PF (1）如drelated com-
pounds.1s.16 PF (1) improved the spatial learning 
deficits produced by unilateral nucleus basalis 
magnocellul紅白（NBM)-lesionand learning impair-
ment in aged (25 months) rats.3 Since PF (1) did not 
induce any other ph紅macologicaleffects at the 
doses tested (0.1-1 mg/kg), the effects of this agent 
on cognitive functions were considered to be highly 
specific. In electrophysiological studies, Tabata 
et al.17 found that PF (1, at a concentration of 
0.1-1 μM) significantly reversed scopolamine-and 
pirenzepine-induced suppression of long-term po-
tentiation (L TP) induction in the CA 1 area in rat 
hippocampus. They suggested that this effect might 
be implicated in the ameliorative effect of PF (1) on 
spatial cognitive impairment caused by cholinergic 
dysfunction in rats. They also suggested出atmodu-
lation, by PF (1), of adenosine Al receptor-
mediated inhibition of L TP in the rat hippocampal 
slice is implicated in its beneficial effect on learn-
ing and memory impairment in rodents.18 PF (1) 
was found to show a very low acute toxicity (LDso 
9.53 and 3.53 g/kg for i.p.組 di. v., respectively). 
These findings strongly suggested that PF (1) has 
beneficial effects in the佐eatmentof dementia. 
Although albiflorin (2, 0.01-1 mg/kg, p・o.),which 
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2. Albitlorin 
has a lactone ring in the pinane skeleton, exhibited 
anticonvulsant activity at smaller doses than PF (1), 
no effect on the maze performance disrupted by 
scopolamine was demonstrated. This observation 
suggested that a cage-like pinane skeleton including 
acetal and hemiketal structure as in PF (1), may 
play加 importantrole in the ameliorating effect of 
these components.16 Morevoer, the ameliorating ef-
fect of PF (1) was markedly enhanced by 
methylation, as in 3-0-methylpaeoniflorin (4) and 
2ム3人5-penta-0-methylpaeoniflorin(5) (Chart 1). 
However, deglucosylation, as in 6-deglucosyl-3-0-
methylpaeoniflorin (6), significantly reduced the 
activity. And removal of both glucose and benzoyl 
moieties resulted in the loss of activity as seen in 
7.19 These results suggested that, in addition to the 
cage-like pinane skeleton, the benzoyl and the 
glucosyl moieties are important structural elements 
of the paeoniflorin skeleton for its effects on spatial 
cognitive dysfunction in rats. 
METABOLISM AND PllARMACOKINETICS 
Since most of the therapeutic effects of peony 
roots訂emainly explained by the pharmacological 
actions of PF (1), and most Kampo medicines are 
orally administered, the metabolic studies on PF 
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(1) and related compounds by intestinal bacteria 
seem to provide insights into the mechanism of 
their therapeutic benefits. Hattori and co-workers 
have collaborated in developing PF (1) and related 
compounds through extensive studies on their me-
tabolism and ph紅macokinetics(either of individual 
compounds or Kampo formulas) in animals and hu-
m組 s.Following 24 hrs anaerobic incubation of PF 
(1) or 3 wi由 ahuman fecal suspension，白reeme-
tabolites, named paeonimetabolins I (PM-I, 11; the 
major metabolite), I (12) and II were obtained 
(Ch制 2）.却 Fecalflora from different subjects 
showed potent metabolic ability but predominantly 
produced由e7S醐diastereomerof PM-I. Most of白e
data showed that the fecal suspensions from aged 
subjects (over 40 years old) consumed PF (1) com” 
pletely but produced relatively smaller amounts 
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(less than 25%) of PM-I compared with those from 
younger subjects. 
A number of bacterial strains isolated from 
human feces showed ability to convert PF (1) to 
paeonimetabolins I and I. Through 10 hrs incuba-
tion of PF (1) with Lactobacillus brevis or 
Bacteroides fragilis, PM-I (11) was obtained in a 
yield of ca. 20% of added PF (1).21 This metabolite 
decreased in創nountduring prolonged incubation 
and disappeared almost completely in 16 hrs. PM-I 
was subsequently separated into 7 R・ and7S-
diastereomers in yields of 11 % and 9.6%, respec-
tively, by column chromatography on silica gel, and 
their s佐uctureswere determined by various spectro-
scopic methods as well as X-ray analysis.21 
Similarly, paeonimetabolin I (12) could be sepa-
rated into the 7R-and 7S-diastereomers. Formation 
日e
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R1=Me, R2=H 
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Chart 2. Possible metabolic pa出wayfor the transformation of PF (1) by Lactobacillus brevis, a human intestinal 
bacterium. 
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of these metabolites from 1 and 3 was initially de-
pends on membrane-bound β田glucosidase(com・
mercially available β－glucosidase from almonds or 
that of animal liver origin hardly hydrolyzed 1 as 
well as l22) to liberate an aglycone which under幽
went reversible conversion of the hemiketal-acetal 
system to ketone, hydroxyl and aldehyde groups. A 
free hydroxyl at C3 is an important prerequisite 
(similar reaction by emulsin, intestinal or soil bacte-
ria was not achieved when the hydroxyl group, CJ-
OH, was methylated) for this conversion which 
seems to be essential for the subsequent steps. 
Then, cleavage of the four-membered ring (C4-Cs-
C6-C1) may be responsible for the formation of a 
new double bond at C1 and Cs and liberation of a 
benzoyl (or a p-hydroxybenzoyl) residue. This key 
intermediate may again cyclize to form a 
hemiketal-acetal system at C1, C6 組 dC9 for 
stereochemical reasons. Non-stereospecific reduc-
tion of the terminal double bond may lead to a mix-
加reof the epimeric 7R-and 7S-PM-I (11). 
It is noteworthy出atthe 7S-isomer of PM-I 
showed a more potent anticonvulsant effect (EDso: 
41.3 mg i.v.) than PF (1, EDso: > 100 mg) in EI 
mice, a model of hereditary epilepsy. When the 
metabolite was given intraduodenally or intraventri-
cularly to rats, the convulsions induced by 
pentylenetetr位 olwere greatly inhibited, and the in-
hibitory effect of PF (1) on the carbachol-induced 
contraction of rat isolated proximal colon was 
found only in vivo. 23・24 These findings emphasize 
the role of intestinal flora in the metabolic activa-
tion of PF (1). Consequently, compounds of this 
unique skeleton have been the t紅getsof consider-
able synthetic activity，組dsynthesis of 7 R-and 7 S 
-PM-I (11) was effectively achieved.25・26 
Since no conversion from 11 to 12 could be 
demonstrated during anaerobic incubation with ei-
ther L. brevis or B. fragilis, the formation of 12 pro-
ceeds via an aldehyde intermediate (ii) and its 
reduced product. The alcohol might cyclize to form 
a hemiketal at the CJ position, followed by non 
stereospecific reduction of the terminal double bond 
to yield the 7 R and 7 S isomers of paeonimetabolin 
I (12) (Ch紅t2).20 Similar to the case of PF (1), 
albiflorin (2) was converted to paeonilactones A 
(13) and B (14) (Chart 3).27 
Akao et al. 28 reported that in the presence of 3-
mercaptopropionic acid, 2-mercaptoethanol and 
thiobenzoic acid (hydroxy, carboxy and 創凶no
担e I 堕e ~e 
。 。
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Chart 3. Possible metabolic pa血wayfor the transformation of albiflorin (2) by Lactobacillus brevis, a human 
intestinal bacterium 
Formation of 16 could be regarded as an ana-
logue of paeoniflorigenone (38) in which 
benzoyl moiety is replaced by a thiobenzoyl group 
and the formation of this adduct in the presence of 
thiobenzoic acid suggests a similar pa白wayforbio-
synthesis of 5 in paeonies. 30-32 For better under-
standing the metabolism and ph紅macokineticsof 
PF (1) and its intestinal bacterial metabolite, PM-I, 
enzyme immunoassay methods for the determina-
tion of PF (1) and PM-I were established.33・34 
Kanaoka et al. 3 used the N-hydroxysuccinimide 
ester method to couple a hemisuccinyl PF deriva-
tive wi出 β－galactosidase(to give a labeled anti-
gen) and a hemiglutaryl PF derivative with BSA (to 
give an immunogen) (Ch制 5).The anti-PF antisera 
were elicited in rabbits by immunization with the 
immunogen, and were used for the determination of 
PF. A satisfactory standard curve for the enzyme 
immunoassay (BIA) of PF was obtained in the 
range of 1-400 ng/ml. The anti唱PFantisera reacted 
with oxypaeoniflorin (3) (0.31 % ) and albiflorin (2) 
(0.22%) (Table 1 ). 
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出e
groups紅eless reactive), the key intermediate (ii), 
reacts in the preference with a mercapto group of 
the compounds by Michael addition, followed by 
the formation of a hemiketal-acetal system and, al-
most equal創nountsof血e7R幽 and7S-isomers of 
15, 16 and 17 could also be obtained. These adduct 
possessed similar s佐UC旬resin which the sultbydryl 
compounds紅ecovalently bound at血eCs position 
of PM-I (11) through a thioether linkage (Chart 4). 
It is interesting to mention that during the course of 
prep紅ingthese compounds, new paeonilactone-A 
adducts (33 -37) were obtained, but only in the 
presence of aromatic thiols. Related adducts of 
paeonilactone-A were not obtained when aliphatic 
thiols were used. 29 Formation of these adducts 企om
PF (1) was presumed to follow the s~e pa白wayas 
in Chart 4 to the key intermediate ii. And this inter-
mediate may be converted to v through iv, possibly 
by redox reaction followed by lactonization. 
Michael addition of aromatic thiols on the double 
bond conjugated with a carbonyl group of v leads to 
the formation of 33-37. 
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3, R = phenyl 
34,R= o・lolyl
35,R= 11-tolyl 
36,R= p・lolyl
37,R= 2・naphthyl
RSH: Aliphatic lhiols 
Aromatic thiols 
25, R = cyclohexyl 
26, R = phenyl 
27, R=o・tolyl
28, R = 11-lolyl 
29, R = p-tolyl 
30, R=2・naphthyl
31, R = benzyl 
32, R = acetyl 
15, R =ethyl 
16, R = benzoyl 
17, R=n・propyl
18, R = i.rn-propyl 
19, R = 1-butyl 
20, R=seι・－butyl
21, R=iso・butyl
2, R = 1-hexyl 
23, R = alyl
24, R = cyclopenlyl 
。
Chart 4. Possible pa出wayfor the formation of thiopaeonnimetabolin-1 derivatives and thiopaeonilactone-A 
derivatives after incubation of PF (1) and thiol compound with Lactobacillus brevis. 
8 
Table 1. Specificity of Anti-PF・BSAAntiserum 
Compound Cross reaction (%) 
Paeoniflorin (1) 100 
Albiflorin (2) 0.22 
Oxypaeoniflorin (3) 0.31 
Paeoniflorigenone (38) 0.10 
Desbenzoylpaeoniflorin (10) 0.03 
Paeoniflorin tetr，鋪cetate 0.0 
Paeoniflorin pen旬acetat旬e 0.01 
Hattori and co-workers developed the EIA 
method of Kanaoka to be used for the determination 
of PM-1.34 The study was accomplished by prep紅ー
ing the carboxymethylthio, carboxyethylthio and 
carboxypentylthio PM-I derivatives, as haptens pos” 
sessing short, medium and long spacers to prep紅e
the BSA-con ugate and labeled antigen (Chart 6). 
Two antisera, named 1CEP and 2CPP, were 
prepared by immunizing rabbits with the co町e-
sponding BSA-conjugates of CEP and CPP. The 
sensitivity was higher in heterologus combinations, 
using the labeled antigens linked with a shorter 
spacer than that used for antiserum production th組
Me 
Glc匂ん／／＼て寸。
円、』 lL H Intestinal bacteria 
γ~宝、O l-IS(CH2)nCOOH 
Bz-O_J - = 
OH 
n= I, 2, 5 
oy< z>.-:. 
PF hemiglutarate-BSA co吋ugate:
X=BSA .. NH, n=3 
PF hemisuccinate-J3-Gal conjugate: 
X=J3-Gal...NH, n=2 
Ch制 5.BSA-andβ－Gal conjugates of PF(l) 
the homologous combinations. The cross reactivities 
of 2CPP against various PM-I related compounds 
were higher th組 thoseof lCEP (Table 2). 
In order to clarify the site(s) of their formation, 
absorption and excretion, Hattori et al戸41carried 
out intensive pharmacokinetic studies of PF (1) and 
its major metabolite, the mixture, 7R-and 7S PM-I 
(ll) in rats. After P・o.and i.v. administration of PF 
(1), the plasma concentrations of PF (1) and PM-I 
were monitored by the respective EIA methods. 
Takeda et al戸 foundthat orally administered PF 
(1) was not metabolized in the gut wall, liver and 
lung, and concluded出at由eunabsorbed fraction of 
HOSl』
CH2S(CH2)nCOOSu 
EDC 
n= 1,2,5 n= I, 2, 5 
PF(I) Carboxytl凶opaeonimetabolin・1
derivatives 
N-Hydroxysuccinimide 
derivatives 
CH2S(CH2)nCONH-
Labeled antigens 
n= 1, 2, 5 
J3-Galactosidase, pH 7.3 
Il 
BSA 
pH 7.3 
CH2S(CH2)nCONH-
BSA-conjugates 
n= l, 2, 5 
Ch紅t6. BSA-andβ－Gal-con ugates of paeonimetabolin-1 
m 
Table 2. Specificity of Anti-PM-I Antisera 
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Compound 
Ant1sera 
Cross reaction (o/c>) 
lCEP 2CPP 
(7R）ー，（7S)-PM・I(11) 
(75トPM-I
(7R)-PM・I
Paeoniflorin (1) 
Paeoniflorigenone (38) 
Benzoylpaeoniflorin 
Oxypaeoniflorin (3) 
Paeoniflorin pentaacetate 
100 
120 
110 
0.02 
0.03 
0.01 
0.02 
0.02 
100 
120 
90 
0.3 
0.5 
1.0 
0.7 
0.02 
38, Paeoniflorigenone 
1 CEP, Carboxyethylthiopaeonimetabolin-1-BSA 
2CPP, carboxypentylthiopaeonimetabolin-1-BSA 
PF (1) was degraded by the intestinal flora to 
paeonimetabolins I-II because of its poor abso中－
tion from the intestine and the extremely low 
bioavailability. A trace amount of PF (1) (Cmax= 95 
ng/ml) was immediately absorbed from the GIT 
after P・o.administration of PF (1) at a dose of 20 
mg/kg, and rapidly eliminated within a short period 
of time (T max= 30 min, disappearance after 240 
min), and a high concentration of PM-I (11) (Cmax 
= 400 ng/ml) was absorbed later and retained in the 
plasma for a longer period (T max= 140 ± 24. 7 min, 
disappearance after 480 min）戸Theplasma concen-
tration of PF (1) after its i. v. administration at a 
dose of 0.5, 2.0 and 5.0 mg/kg declined rapidly 
with mean terminal half-lives of 11.0, 9.9 and 12.6 
min, respectively, and plasma concentration time 
curve obtained was best described by a two-
comp訂tmentmodel at each dose. 37-39 Plasma con-
centration of PM-I (11) was higher than that of PF 
(1) at each dose, and reached the Cmax after the time 
when most of the PF (1) was eliminated (Table 3). 
PM-I (11) was retained in the plasma at higher con-
ce附 ationfor a relatively longer time than PF. -rpe 
plasma concentration profiles after intraportal ad-
ministration of PF (1) was very close to those after 
i. v. administration, suggesting a negligible hepatic 
extraction ration of PF (1) [supported by the fact 
that PF (1) is not degraded after incubation with a 
rat liver homogenate]. 35 
Since the AUC value, from time zero to infin-
ity, by the intraperitoneal route (24.5土2.91μgl 
min/ml) is not less than that after intraportal ad-
ministration ( 19.1士2.60mg/min/ml), PF (1) seems 
not to be metabolized in gut wall. 35 The oral 
bioavailability of PF (1) was very low (3-4%) when 
calculated by A UCs after P・o.or i.v. administration 
(agreed with白atrepoi:ted in rabbits41) and ex-
tremely low fecal excretion (0.07-0.22%) is ob-
served. This low bioavailability might be induced 
by the first-pass effects in the gut wall and liver or 
by the bacterial degradation of PF (1), which has 
the opportunity to occur due to poor intestinal ab-
so中tion戸，38The plasma concentration of PF (1) 
after usual oral dosing was very low ( Cmax= 9 .8,
30.7 and 101.5 ng/ml at 0.5, 2.0 and 5.0 mg/kg, re-
spectively) when compared with that after i.v. dos-
Table 3. Pharmacokinetic Parameters of Paeoniflorin (1) and Paeonimetabolin I (11) after 
Oral Administration of Paeoniflorin (0.5 and 5 mg/kg) to Rats 
Parameter ? ?? ?
Cmax (ng/ml) 
Tmax (min) 
AUCo・1so(ng.min/ml) 
9.9±2.2 
11.6±1.7 
300±79 
163.5±2.64 
60±0.0 
1873±176.8 
20.3±2.7 
13.3±1.7 
1174±287 
101.7±26.4 
80±10.2 
12358土3564
Each value represents mean±S.E (n= 3). 
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ing.38 Following i.v. administration of PF (1) to rats, 
as much as 50% of the dose was excreted in urine 
and 0.22% was excreted in the feces within 72 hrs, 
while 1.0 and 0.08% was, respectively, excreted 
after P・O・administrationwithin 48 hrs. 37 Cumulative 
biliary excretion after i. v. or P・o.administration was 
6.9 and 1.3% of the dose (0.5 mg/ kg) within 24 
hrs, respectively, and suggesting an enterohepatic 
cycling may occur.38 In germ-free rats, PF (1) was 
rapidly absorbed as well as in conventional rats, but 
the plasma concentration was kept at the nearly 
constant level around 25 ng/ml for 240 min after 
P・o.adminis住ation,and a significant difference of 
plasma concentrations between germ－仕eeand con-
ventional rats was observed (Table 4).41 
When the kinetics of PM田I(11) were inde-
pendently investigated, appreciable increase in the 
plasma concentration of PM田Iwas observed after 
P・o.or i.v. administration of PM”I (0.2 and 2 mg/kg) 
(Table 5), which then decreased and followed by a 
long elimination half lives (240.6 and 229.5 min, 
respectively) and the curves were well fitted to the 
two-comp紅tmentmodel at each dose.40・41 
The disposition of PF and its m吋ormetabolite, 
PM-I in rats was investigated, after P・o.administra-
tion of traditional Chinese prescriptions containing 
paeony root. Shakuyaku-kanzo-to (SK), a prescrip-
tion contained equal amounts of paeony root and 
licorice root, while Toki-shakuyaku-san (TS) con-
tained peony root mixed with other 5 herbal drugs 
Table 4. Pharmacokinetic Parameters of Paeoniflorin (1) in Germ-free and Conventional Rats after 
2 mg/kg Oral Administration of PF (1). 
Rat 
Conventional 
Germ－合ee
n 
6 
3 
Cmax Tmax 
(ng/ml) (min) 
32.7±04.1 
42.3±11.5 
10士01.8
130士60.8
AUCo・240
(ng.min/ml) 
2799.7±276.6 
5528土1461.8*
但!El
40.2±6.1 
：ー notcalculated; Each value represents mean±S.E.; *pく0.05: significantly different from conventional rat 
Table 5. Pharmacokinetic Parameters of Paeonimetabolin I (11) after 0.2 and 2 mg/kg Oral 
Administration of Paeonimetabolin I toRats 
Parameter Dose {mg/kg} 
0.2 2 
Cmax (ng/ml) 102±17.0 285±41.7 
Tmax (min) 6.2±1.3 7.5±1.4 
1112 (min) 240.6±137 229.5±58.5 
AUCo・1so(ng.min/ml) 4145.6±973.7 14182.1±1642 
F 0.8±0.15 1.07±0.07 
Each value represents mean±S.E (n= 3, 4). 
Table 6. Pharmacokinetic Parameters of PF (1) and PM-I (11) after Oral Administration of TS 
and SK at Doses of 100 and 500 mg to Rats. 
Cmax fm似 112 AUCo・24h
Prescription {ng/ml) (min) (min) (ng・min/ml) 
TS (100 mg) PF (1) 146.3 60 140.3 14305 
PM-I (11) 184.0 120 426.7 98497 
(500 mg) PF (1) 165.l 45 970.0 19385 
PM-I (11) 400.3 180 569.l 182188 
SK(lOO mg) PF (1) 128.5 5 921.2 48857 
PM-I (11) 141.7 360 508.7 102136 
(500 mg) PF (1) 153.5 5 69.1 32518 
PM-I (11) 726.5 480 325.8 469305 
1 
Table 7. Anticonvulsant Potency and Neurotoxicity of 16 (7 S) and 22 (7 S) 
Parameter PF 0.5 mg/kg PF 5 mg/kg 
PF (1) PM-I (11) PF (1) PM・I(11) 
Cmax {ng/ml) 
Tmax (min) 
AUCo・1so(ng.min/ml) 
9.9±2.2 
11.6±1.7 
300±79 
Each value represents mean±S.E {n= 3). 
but no licorice root.42 It was clear that the plasma 
concentrations and the AUC values of PM-I were 
higher than those of PF (Table 6). Another impor-
tant finding was that the effects of the two formulas 
on the disposition of PM-I were significantly differ-
ent. The maximal plasma concentration of PM-I ap-
pe紅・edat 360-480 min in the case of SK and at 120-
180 min in TS. The decline of the PF level was very 
slow when SK was given but very fast when TS 
was given. The Cmax of PF in the plasma was at 5 
min when SK was given, while the shoulder peak at 
5 min when TS was given. These difference can be 
explained by the fact that SK affects the gastric 
emptying rate, the peristaltic movement of the small 
intestine which delayed the time for PF to reach the 
large intestine where most of PF was metabolized 
to PM-I by intestinal bacteria. 
APPLICATION OF BACTERIAL TRANSFORMATION 
TO THE DEVELOPMENT OF NEW DRUGS 
Although efficient chemical processes 訂e
available for the synthesis of PF (1)10・1 and its 
m勾ormetabolite, PM-I, 25・26 chemical reactions C訂－
ried out by intestinal bacteria offer a promising 
method for developing these compounds. As men-
tioned earlier, the 7S・isomerof PM-I, showed 
anticonvulsant activity in EI mice, an animal model 
of heredity epilepsy. Attempts have been made to 
improve the anticonvulsant activity of PM-I by 
using intestinal bacterial reactions. In the presence 
of various thiol compounds (RSH, where R = ali-
phatic and aromatic groups), Ltictobacillus brevis, a 
human intestinal bacterium, showed high ability to 
transform PF (1) into seventeen thiopaeonimetabolin-
I derivatives (16-32) (with preference for the 7 S-
isomers (Chart 4).43・4 When the anticonvulsant 
activity of these derivatives was investigated in 
163.5±2.64 
60±0.0 
1873±176.8 
20.3±2.7 
13.3±1.7 
1174士287
101.7土26.4
80±10.2 
12358±3564 
mice using the maximal subcutanous pentylenetet-
razol seizure test, 13 compounds (16-22, 24, 26-
30) showed dose-dependent prolongation of laten-
cies of clonic and tonic convulsions in a concen佐a-
tion range of 0.125-0.5 mmol/kg. It was app紅ent
that introduction of an R-thio residue at C-8 of PM-
I effectively enhanced its anticonvulsant activity. 
For the most potent anticonvulsant adducts (16 
and 22), a marked stereospecificity was noticed, 
where the 7S-isomers displayed anticonvulsant ac-
tivity while the diasteroisomers (7R-ones) showed 
skeletal muscle relaxation effect.44 When the EDso 
values of the 7S-isomers of 16加 d22 were com-
pared with that of valproic acid (VP A), 16 (7 S) and 
22 (7S) were approximately 11.7 and 8.8-times as 
active as VPA, respectively (Table 7). Furthermore, 
the higher protective indices (4.0 and 5.0, repectively) 
for 16 (7S) and 22 (7S), when comp訂edwith that 
of VPA (Pl= 1.8), suggested that the maximal 
anticonvulsant effect of these compounds was 
achieved at non-toxic doses. 
CONCLUSION 
Paeoniflorin (PF, 1 ), the m吋ormonoterpene 
glycoside in peony roots, is a promising compound 
that demonstrates neuropharmacological effects in 
rodents, beside its activity as muscle relaxant, anti-
spasmodic, and antiinflammatory agent. It is note-
worthy to mention that methylation of PF (1) 
enhanced its antiamnesic action, possibly by in-
creasing its lipophilicity and bioavilability. But, 
because of its poor absorption from the small intes-
tine, metabolism of PF (1) by intestinal bacteria 
gave three metabolites, paeonimetabolin I-II. PM-I 
(11), its major intestinal bacterial metabolite, was 
detected in rat plasma at higher concentrations than 
that of PF after oral administration of PF (1) or 
12 
herbal prescriptions containing peony root. When 
comp訂ed with PF, PM-I showed a potent 
anticonvulsant activity. Moreover, transformation 
of PF (1) by intestinal bacteria in the presence of 
various thiol compounds was conveniently ex-
ploited for the prep訂ation of more potent 
anticonvulsant thiopaeonimetabolin-I derivatives, 
which are otherwise inaccessible. 
Although it is too early to draw a conclusion, 
the above findings suggested possible utilization of 
PF (1) in the仕eatmentof certain types of dementia 
and other CNS disorders. 
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